Precision Antibody has an exclusive license agreement with trans-chromosomic (Tc) mice carrying mini-chromosomes with megabase-sized human immunoglobulin (Ig) loci. Precision Antibody has developed a proprietary method to develop a strong immune response against therapeutic targets in three weeks, enabling fully human therapeutic antibody development in ~60 days. Through comprehensive, high-throughput DNA sequencing, it has been shown that the human Ig repertoire is well recapitulated in TC-mAb mice. TC-mAb mice have more subsets of antigen-specific plasmablast and plasma cells than wild-type mice, thus leading to efficient hybridoma production.
To learn more about TC-mAb mice, click below to read the full Nature article.
